Virginia / 2026 Regular Session

2026 Regular Session · Imported snapshot

SB278: Federal 340B Drug Pricing Program; impacts within the Commonwealth.

signed by governor

<b>Drug manufacturers; 340B Drug Pricing Program; work group; report.</b> Directs the Secretary of Health and Human Resources to convene a work group to conduct a comprehensive evaluation of the impacts of the federal 340B Drug Pricing Program within the Commonwealth, with emphasis on governance, transparency, and the availability of pharmacy services in rural and underserved areas. The bill requires the work group to submit a report on its findings and recommendations to the Chairs of the Senate Committees on Finance and Appropriations and Education and Health and the House Committees on Appropriations and Health and Human Services by November 1, 2026.

Official bill page · Source: Richmond Sunlight

Ask about SB278

Full bill text

Version CHAP0887 · 2026-04-13

Full text

Changes in this version: added text deleted text

An Act to direct the Secretary of Health and Human Resources to convene a stakeholder work group to conduct a comprehensive evaluation of the impacts of the federal 340B Drug Pricing Program within the Commonwealth; report.

Be it enacted by the General Assembly of Virginia:

1. § 1. That the Secretary of Health and Human Resources (the Secretary), in consultation with the Department of Health Professions, the Board of Pharmacy, and the Department of Medical Assistance Services, shall convene a stakeholder work group to conduct a comprehensive evaluation of the impacts of the federal 340B Drug Pricing Program within the Commonwealth with emphasis on governance, transparency, and the availability of pharmacy services in rural and underserved communities. The work group shall include representatives from the Virginia Community Healthcare Association, the Virginia Hospital and Healthcare Association, the Virginia Society of Health-System Pharmacists, the Virginia Community Pharmacy Association, Federally Qualified Health Centers (FQHCs), Pharmaceutical Research and Manufacturers of America, the Virginia Biotechnology Association, the Virginia Association of Health Plans, the Virginia Association of Chain Drug Stores, the Virginia Pharmacists Association, and other stakeholders with relevant expertise in the administration, oversight, or compliance requirements of the federal 340B Drug Pricing Program.

§ 2. In conducting the evaluation, the work group shall review the following:

1. Federal statutory, regulatory, and guidance-based requirements applicable to 340B covered entities, pharmaceutical manufacturers, and contract pharmacies, including transparency, reporting, auditing, and compliance obligations administered by the U.S. Health Resources and Services Administration;

2. The number and location of covered entities as defined by the Public Health Service Act, 42 U.S.C. § 256b, in the Commonwealth;

3. The number and location of contract pharmacies in the Commonwealth and their association to a covered entity;

4. Transparency and governance requirements that could be adopted on the state level to ensure transparent and authorized conduct in accordance with the stated purpose of the 340B Drug Pricing Program, including mechanisms to prevent diversion of Medicaid patients and duplicate discounts between the 340B Drug Pricing Program and Medicaid;

5. The role of contract pharmacies within the 340B Drug Pricing Program in the Commonwealth, including their functions related to patient access to prescription drugs and care coordination;

6. Potential state-level actions to ensure revenue from the 340B Drug Pricing Program is used by covered entities and contract pharmacies in furtherance of the stated goals of the enabling § 340B of the federal Public Health Service Act, 42 U.S.C. § 256b, to enable covered entities to stretch scarce federal resources as far as possible;

7. The types of contractual arrangements between covered entities and contract pharmacies, including dispensing fees, administrative fees and payments, and financial practices;

8. Limitations that may be placed on the use and number of contract pharmacy arrangements utilized by covered entities, taking into consideration patient need, geographic access, provider type, and differences between urban, suburban, rural, and underserved areas of the Commonwealth. This assessment shall include analysis of the relationship between covered entities and contract pharmacies to ensure that such relationships support care for low-income and underserved individuals and provide sufficient transparency; and

9. The operational, administrative, and fiscal impact of any recommendations provided by the work group on covered entities, particularly safety-net providers and providers serving rural or underserved populations.

§ 3. The Secretary shall submit a report on the work group's findings and recommendations to the Chairs of the Senate Committees on Finance and Appropriations and Education and Health and the House Committees on Appropriations and Health and Human Services no later than November 1, 2026.

Legislative actions

2026-01-28 · history

Senate subcommittee offered

2026-02-13 · history

Engrossed by Senate - committee substitute (Voice Vote)

2026-02-23 · history

Assigned sub: Health

2026-02-19 · history

Read first time

2026-01-30 · history

Committee substitute printed 26106505D-S1

2026-03-02 · history

Read second time

2026-02-24 · history

Subcommittee recommends reporting with amendment(s)

2026-03-11 · history

Enrolled

2026-02-26 · history

Reported from Health and Human Services with amendment(s) (21-Y 0-N)

2026-02-13 · history

Read second time

2026-03-03 · history

Read third time

2026-01-29 · history

Senate committee offered

2026-04-13 · history

Acts of Assembly Chapter text (CHAP0887)

2026-04-13 · history

Approved by Governor-Chapter 887 (effective 7/1/2026)

2026-01-13 · history

Prefiled and ordered printed; Offered 01-14-2026 26102079D

2026-02-13 · history

Committee substitute printed 26107756D-S2

2026-03-03 · history

Engrossed by House as amended

2026-02-24 · history

Subcommittee recommends reporting with amendment(s) (10-Y 0-N)

2026-02-13 · history

Committee substitute agreed to (Voice Vote)

2026-01-29 · history

Reported from Education and Health with substitute and rereferred to Finance and Appropriations

2026-02-12 · history

Passed by for the day

2026-01-27 · history

Fiscal Impact Statement from Department of Planning and Budget (SB278)

2026-01-13 · history

Referred to Committee on Education and Health

2026-02-12 · history

Passed by for the day Block Vote (Voice Vote)

2026-02-23 · history

Fiscal Impact Statement from Department of Planning and Budget (SB278)

2026-03-05 · history

House amendments agreed to by Senate (39-Y 0-N 0-A)

2026-02-19 · history

Referred to Committee on Health and Human Services

2026-01-20 · history

Assigned Education sub: Health

2026-02-16 · history

Read third time and passed Senate (39-Y 0-N 0-A)

2026-02-11 · history

Reported from Finance and Appropriations with substitute

2026-01-29 · history

Reported from Education and Health with substitute and rereferred to Finance and Appropriations (9-Y 0-N 6-A)

2026-03-03 · history

committee amendments agreed to

2026-03-03 · history

Passed House with amendments Block Vote (97-Y 0-N 0-A)

2026-02-26 · history

Reported from Health and Human Services with amendment(s)

2026-03-14 · history

Enrolled Bill communicated to Governor on March 14, 2026

2026-02-12 · history

Constitutional reading dispensed Block Vote (on 1st reading) (40-Y 0-N 0-A)

2026-03-12 · history

Signed by Speaker

2026-02-11 · history

Reported from Finance and Appropriations with substitute (15-Y 0-N)

2026-02-19 · history

Placed on Calendar

2026-02-24 · history

House subcommittee offered

2026-02-13 · history

Engrossed by Senate (Voice Vote)

2026-02-12 · history

Rules suspended

2026-03-11 · history

Signed by President

2026-03-11 · history

Bill text as passed Senate and House (SB278ER)

2026-03-11 · history

Fiscal Impact Statement from Department of Planning and Budget (SB278)

2026-03-14 · history

Governor's Action Deadline 11:59 p.m., April 13, 2026

2026-02-13 · history

Committee substitute rejected (Voice Vote)

Raw source record
{
    "id": 84938,
    "url": "https:\/\/www.richmondsunlight.com\/bill\/2026\/sb278\/",
    "tags": {
        "150528": "drugs",
        "150529": "regulation",
        "150530": "healthcare",
        "150531": "pharmacy",
        "150532": "registration",
        "150533": "manufacturers"
    },
    "text": [
        {
            "date": "2026-01-13",
            "number": "SB278",
            "pdf_url": "https:\/\/downloads.richmondsunlight.com\/bills\/2026\/sb278.pdf"
        },
        {
            "date": "2026-01-30",
            "number": "SB278S1"
        },
        {
            "date": "2026-02-13",
            "number": "SB278S2"
        },
        {
            "date": "2026-03-11",
            "number": "SB278ER"
        },
        {
            "date": "2026-04-13",
            "number": "CHAP0887"
        }
    ],
    "type": "bill",
    "year": 2026,
    "video": null,
    "number": "sb278",
    "patron": "Srinivasan, Kannan",
    "status": "signed by governor",
    "chamber": "senate",
    "changes": null,
    "outcome": "passed",
    "related": [
        {
            "id": 85357,
            "name": "Education and Health",
            "year": 2026,
            "count": 4,
            "number": "sb379",
            "status": "signed by governor",
            "catch_line": "Psilocybin; Board of Pharmacy to reschedule upon federal scheduling changes.",
            "date_introduced": "January 13, 2026"
        },
        {
            "id": 85075,
            "name": "Commerce and Labor",
            "year": 2026,
            "count": 3,
            "number": "hb1172",
            "status": "failed committee",
            "catch_line": "Pharmacy freedom of choice; specialty pharmacy benefits.",
            "date_introduced": "January 14, 2026"
        },
        {
            "id": 85388,
            "name": "Education and Health",
            "year": 2026,
            "count": 3,
            "number": "sb410",
            "status": "incorporated",
            "catch_line": "Pharmacy benefits managers; various requirements; report.",
            "date_introduced": "January 13, 2026"
        },
        {
            "id": 84874,
            "name": null,
            "year": 2026,
            "count": 3,
            "number": "hb1025",
            "status": "failed committee",
            "catch_line": "Access to investigational drugs, etc.; patient with severely debilitating condition.",
            "date_introduced": "January 14, 2026"
        },
        {
            "id": 85717,
            "name": "Finance",
            "year": 2026,
            "count": 3,
            "number": "sb668",
            "status": "failed committee",
            "catch_line": "State pharmacy benefits manager; contractual provisions, report.",
            "date_introduced": "January 14, 2026"
        }
    ],
    "summary": "<b>Drug manufacturers; 340B Drug Pricing Program; work group; report.<\/b> Directs the Secretary of Health and Human Resources to convene a work group to conduct a comprehensive evaluation of the impacts of the federal 340B Drug Pricing Program within the Commonwealth, with emphasis on governance, transparency, and the availability of pharmacy services in rural and underserved areas. The bill requires the work group to submit a report on its findings and recommendations to the Chairs of the Senate Committees on Finance and Appropriations and Education and Health and the House Committees on Appropriations and Health and Human Services by November 1, 2026.",
    "version": "CHAP0887",
    "copatron": [
        {
            "shortname": "rtwillett",
            "partisanship": 18,
            "name_formatted": "Del. Rodney Willett (D-Henrico)"
        },
        {
            "shortname": "ldaird",
            "partisanship": 26,
            "name_formatted": "Sen. Lashrecse D. Aird (D-Petersburg)"
        },
        {
            "shortname": "bafavola",
            "partisanship": 26,
            "name_formatted": "Sen. Barbara Favola (D-Arlington)"
        },
        {
            "shortname": "lllucas",
            "partisanship": 34,
            "name_formatted": "Sen. Louise Lucas (D-Portsmouth)"
        },
        {
            "shortname": "sasalim",
            "partisanship": 24,
            "name_formatted": "Sen. Saddam Azlan Salim (D-Fairfax)"
        }
    ],
    "committee": "Finance",
    "full_text": "<p class=\"ldtitle\">An Act to direct the Secretary of Health and Human Resources to convene a stakeholder work group to conduct a comprehensive evaluation of the impacts of the federal 340B Drug Pricing Program within the Commonwealth; report.<\/p><p class=\"enactstm\">Be it enacted by the General Assembly of Virginia:<\/p><p class=\"textbl\"><strong>1. <\/strong><em class=\"new\">\u00a7 1. That the Secretary of Health and Human Resources (the Secretary), in consultation with the Department of Health Professions, the Board of Pharmacy, and the Department of Medical Assistance Services, shall convene a stakeholder work group to conduct a comprehensive evaluation of the impacts of the federal 340B Drug Pricing Program within the Commonwealth with emphasis on governance, transparency, and the availability of pharmacy services in rural and underserved communities. The work group shall include representatives from the Virginia Community Healthcare Association, the Virginia Hospital and Healthcare Association, the Virginia Society of Health-System Pharmacists, the Virginia Community Pharmacy Association, Federally Qualified Health Centers (FQHCs), Pharmaceutical Research and Manufacturers of America, the Virginia Biotechnology Association, the Virginia Association of Health Plans, the Virginia Association of Chain Drug Stores, the Virginia Pharmacists Association, and other stakeholders with relevant expertise in the administration, oversight, or compliance requirements of the federal 340B Drug Pricing Program.<\/ins><\/p><p class=\"section\"><em class=\"new\">\u00a7 2. In conducting the evaluation, the work group shall review the following:<\/ins><\/p><p class=\"section\"><em class=\"new\">1. Federal statutory, regulatory, and guidance-based requirements applicable to 340B covered entities, pharmaceutical manufacturers, and contract pharmacies, including transparency, reporting, auditing, and compliance obligations administered by the U.S. Health Resources and Services Administration;<\/ins><\/p><p class=\"section\"><em class=\"new\">2. The number and location of covered entities as defined by the Public Health Service Act, 42 U.S.C. \u00a7 256b, in the Commonwealth;<\/ins><\/p><p class=\"section\"><em class=\"new\">3. The number and location of contract pharmacies in the Commonwealth and their association to a covered entity; <\/ins><\/p><p class=\"section\"><em class=\"new\">4. Transparency and governance requirements that could be adopted on the state level to ensure transparent and authorized conduct in accordance with the stated purpose of the 340B Drug Pricing Program, including mechanisms to prevent diversion of Medicaid patients and duplicate discounts between the 340B Drug Pricing Program and Medicaid; <\/ins><\/p><p class=\"section\"><em class=\"new\">5. The role of contract pharmacies within the 340B Drug Pricing Program in the Commonwealth, including their functions related to patient access to prescription drugs and care coordination;<\/ins><\/p><p class=\"section\"><em class=\"new\">6. Potential state-level actions to ensure revenue from the 340B Drug Pricing Program is used by covered entities and contract pharmacies in furtherance of the stated goals of <em>the enabling \u00a7 340B of the federal Public Health Service Act, 42 U.S.C. \u00a7 256b, to enable covered entities to stretch scarce federal resources as far as possible<\/ins>;<\/ins><\/p><p class=\"section\"><em class=\"new\">7. The types of contractual arrangements between covered entities and contract pharmacies, including dispensing fees, administrative fees and payments, and financial practices;<\/ins><\/p><p class=\"section\"><em class=\"new\">8. Limitations that may be placed on the use and number of contract pharmacy arrangements utilized by covered entities, taking into consideration patient need, geographic access, provider type, and differences between urban, suburban, rural, and underserved areas of the Commonwealth. This assessment shall include analysis of the relationship between covered entities and contract pharmacies to ensure that such relationships support care for low-income and underserved individuals and provide sufficient transparency; and<\/ins><\/p><p class=\"section\"><em class=\"new\">9. The operational, administrative, and fiscal impact of any recommendations provided by the work group on covered entities, particularly safety-net providers and providers serving rural or underserved populations.<\/ins><\/p><p class=\"section\"><em class=\"new\">\u00a7 3. The Secretary shall submit a report on the work group's findings and recommendations to the Chairs of the Senate Committees on Finance and Appropriations and Education and Health and the House Committees on Appropriations and Health and Human Services no later than November 1, 2026.<\/ins><\/p>",
    "catch_line": "Federal 340B Drug Pricing Program; impacts within the Commonwealth.",
    "duplicates": null,
    "session_id": 32,
    "word_count": 677,
    "patron_party": "D",
    "patron_place": "Broadlands",
    "summary_hash": "36c448d0ad6e81008152d5a2af5e5e28",
    "patron_prefix": "Sen.",
    "patron_suffix": "(D-Broadlands)",
    "status_detail": "signed by governor",
    "_rsun_versions": [
        {
            "id": "a38339c2c372590e03364aeb5bdeb251eef265427e58873fbeeec337c9891e6b",
            "code": "CHAP0887",
            "bill_id": 84938,
            "source_url": null,
            "source_date": "2026-04-13",
            "source_hash": "854aa5fe3dd14c863d9df9f08f152faa4b6dddea4f612515b83c7200242b4079",
            "source_html": "<p class=\"ldtitle\">An Act to direct the Secretary of Health and Human Resources to convene a stakeholder work group to conduct a comprehensive evaluation of the impacts of the federal 340B Drug Pricing Program within the Commonwealth; report.<\/p><p class=\"enactstm\">Be it enacted by the General Assembly of Virginia:<\/p><p class=\"textbl\"><strong>1. <\/strong><em class=\"new\">\u00a7 1. That the Secretary of Health and Human Resources (the Secretary), in consultation with the Department of Health Professions, the Board of Pharmacy, and the Department of Medical Assistance Services, shall convene a stakeholder work group to conduct a comprehensive evaluation of the impacts of the federal 340B Drug Pricing Program within the Commonwealth with emphasis on governance, transparency, and the availability of pharmacy services in rural and underserved communities. The work group shall include representatives from the Virginia Community Healthcare Association, the Virginia Hospital and Healthcare Association, the Virginia Society of Health-System Pharmacists, the Virginia Community Pharmacy Association, Federally Qualified Health Centers (FQHCs), Pharmaceutical Research and Manufacturers of America, the Virginia Biotechnology Association, the Virginia Association of Health Plans, the Virginia Association of Chain Drug Stores, the Virginia Pharmacists Association, and other stakeholders with relevant expertise in the administration, oversight, or compliance requirements of the federal 340B Drug Pricing Program.<\/ins><\/p><p class=\"section\"><em class=\"new\">\u00a7 2. In conducting the evaluation, the work group shall review the following:<\/ins><\/p><p class=\"section\"><em class=\"new\">1. Federal statutory, regulatory, and guidance-based requirements applicable to 340B covered entities, pharmaceutical manufacturers, and contract pharmacies, including transparency, reporting, auditing, and compliance obligations administered by the U.S. Health Resources and Services Administration;<\/ins><\/p><p class=\"section\"><em class=\"new\">2. The number and location of covered entities as defined by the Public Health Service Act, 42 U.S.C. \u00a7 256b, in the Commonwealth;<\/ins><\/p><p class=\"section\"><em class=\"new\">3. The number and location of contract pharmacies in the Commonwealth and their association to a covered entity; <\/ins><\/p><p class=\"section\"><em class=\"new\">4. Transparency and governance requirements that could be adopted on the state level to ensure transparent and authorized conduct in accordance with the stated purpose of the 340B Drug Pricing Program, including mechanisms to prevent diversion of Medicaid patients and duplicate discounts between the 340B Drug Pricing Program and Medicaid; <\/ins><\/p><p class=\"section\"><em class=\"new\">5. The role of contract pharmacies within the 340B Drug Pricing Program in the Commonwealth, including their functions related to patient access to prescription drugs and care coordination;<\/ins><\/p><p class=\"section\"><em class=\"new\">6. Potential state-level actions to ensure revenue from the 340B Drug Pricing Program is used by covered entities and contract pharmacies in furtherance of the stated goals of <em>the enabling \u00a7 340B of the federal Public Health Service Act, 42 U.S.C. \u00a7 256b, to enable covered entities to stretch scarce federal resources as far as possible<\/ins>;<\/ins><\/p><p class=\"section\"><em class=\"new\">7. The types of contractual arrangements between covered entities and contract pharmacies, including dispensing fees, administrative fees and payments, and financial practices;<\/ins><\/p><p class=\"section\"><em class=\"new\">8. Limitations that may be placed on the use and number of contract pharmacy arrangements utilized by covered entities, taking into consideration patient need, geographic access, provider type, and differences between urban, suburban, rural, and underserved areas of the Commonwealth. This assessment shall include analysis of the relationship between covered entities and contract pharmacies to ensure that such relationships support care for low-income and underserved individuals and provide sufficient transparency; and<\/ins><\/p><p class=\"section\"><em class=\"new\">9. The operational, administrative, and fiscal impact of any recommendations provided by the work group on covered entities, particularly safety-net providers and providers serving rural or underserved populations.<\/ins><\/p><p class=\"section\"><em class=\"new\">\u00a7 3. The Secretary shall submit a report on the work group's findings and recommendations to the Chairs of the Senate Committees on Finance and Appropriations and Education and Health and the House Committees on Appropriations and Health and Human Services no later than November 1, 2026.<\/ins><\/p>",
            "source_metadata": {
                "bodyAssociation": "archive-reported-current-version",
                "archiveReference": {
                    "date": "2026-04-13",
                    "number": "CHAP0887"
                }
            }
        }
    ],
    "copatron_count": 5,
    "patron_address": [
        "P.O. Box 4268",
        "Broadlands",
        "VA 20148"
    ],
    "patron_chamber": "senate",
    "patron_started": 2025,
    "session_lis_id": 261,
    "status_history": [
        {
            "date": "04\/13\/2026",
            "status": "Acts of Assembly Chapter text (CHAP0887)",
            "date_raw": "2026-04-13",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "04\/13\/2026",
            "status": "Approved by Governor-Chapter 887 (effective 7\/1\/2026)",
            "date_raw": "2026-04-13",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": "signed by governor"
        },
        {
            "date": "03\/14\/2026",
            "status": "Governor's Action Deadline 11:59 p.m., April 13, 2026",
            "date_raw": "2026-03-14",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "03\/14\/2026",
            "status": "Enrolled Bill communicated to Governor on March 14, 2026",
            "date_raw": "2026-03-14",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "03\/12\/2026",
            "status": "Signed by Speaker",
            "date_raw": "2026-03-12",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "03\/11\/2026",
            "status": "Signed by President",
            "date_raw": "2026-03-11",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": "passed"
        },
        {
            "date": "03\/11\/2026",
            "status": "Fiscal Impact Statement from Department of Planning and Budget (SB278)",
            "date_raw": "2026-03-11",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "03\/11\/2026",
            "status": "Bill text as passed Senate and House (SB278ER)",
            "date_raw": "2026-03-11",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "03\/11\/2026",
            "status": "Enrolled",
            "date_raw": "2026-03-11",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "03\/05\/2026",
            "status": "House amendments agreed to by Senate (39-Y 0-N 0-A)",
            "date_raw": "2026-03-05",
            "vote_count": null,
            "lis_vote_id": "300740",
            "translation": null
        },
        {
            "date": "03\/03\/2026",
            "status": "Passed House with amendments  Block Vote (97-Y 0-N 0-A)",
            "date_raw": "2026-03-03",
            "vote_count": null,
            "lis_vote_id": "300103",
            "translation": "passed house"
        },
        {
            "date": "03\/03\/2026",
            "status": "Engrossed by House as amended",
            "date_raw": "2026-03-03",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "03\/03\/2026",
            "status": "committee amendments agreed to",
            "date_raw": "2026-03-03",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "03\/03\/2026",
            "status": "Read third time",
            "date_raw": "2026-03-03",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "03\/02\/2026",
            "status": "Read second time",
            "date_raw": "2026-03-02",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "02\/26\/2026",
            "status": "Reported from Health and Human Services with amendment(s) (21-Y 0-N)",
            "date_raw": "2026-02-26",
            "vote_count": null,
            "lis_vote_id": "299130",
            "translation": "passed committee"
        },
        {
            "date": "02\/26\/2026",
            "status": "Reported from Health and Human Services with amendment(s)",
            "date_raw": "2026-02-26",
            "vote_count": null,
            "lis_vote_id": "299130",
            "translation": "passed committee"
        },
        {
            "date": "02\/24\/2026",
            "status": "Subcommittee recommends reporting with amendment(s) (10-Y 0-N)",
            "date_raw": "2026-02-24",
            "vote_count": null,
            "lis_vote_id": "298630",
            "translation": "passed subcommittee"
        },
        {
            "date": "02\/24\/2026",
            "status": "Subcommittee recommends reporting with amendment(s)",
            "date_raw": "2026-02-24",
            "vote_count": null,
            "lis_vote_id": "298630",
            "translation": "passed subcommittee"
        },
        {
            "date": "02\/24\/2026",
            "status": "House subcommittee offered",
            "date_raw": "2026-02-24",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "02\/23\/2026",
            "status": "Fiscal Impact Statement from Department of Planning and Budget (SB278)",
            "date_raw": "2026-02-23",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "02\/23\/2026",
            "status": "Assigned sub: Health",
            "date_raw": "2026-02-23",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": "in subcommittee"
        },
        {
            "date": "02\/19\/2026",
            "status": "Referred to Committee on Health and Human Services",
            "date_raw": "2026-02-19",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": "in committee"
        },
        {
            "date": "02\/19\/2026",
            "status": "Read first time",
            "date_raw": "2026-02-19",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "02\/19\/2026",
            "status": "Placed on Calendar",
            "date_raw": "2026-02-19",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "02\/16\/2026",
            "status": "Read third time and passed Senate (39-Y 0-N 0-A)",
            "date_raw": "2026-02-16",
            "vote_count": null,
            "lis_vote_id": "297562",
            "translation": "passed senate"
        },
        {
            "date": "02\/13\/2026",
            "status": "Engrossed by Senate - committee substitute (Voice Vote)",
            "date_raw": "2026-02-13",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "02\/13\/2026",
            "status": "Engrossed by Senate (Voice Vote)",
            "date_raw": "2026-02-13",
            "vote_count": null,
            "lis_vote_id": "297287",
            "translation": null
        },
        {
            "date": "02\/13\/2026",
            "status": "Committee substitute agreed to (Voice Vote)",
            "date_raw": "2026-02-13",
            "vote_count": null,
            "lis_vote_id": "297286",
            "translation": null
        },
        {
            "date": "02\/13\/2026",
            "status": "Committee substitute rejected (Voice Vote)",
            "date_raw": "2026-02-13",
            "vote_count": null,
            "lis_vote_id": "297285",
            "translation": null
        },
        {
            "date": "02\/13\/2026",
            "status": "Read second time",
            "date_raw": "2026-02-13",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "02\/13\/2026",
            "status": "Committee substitute printed 26107756D-S2",
            "date_raw": "2026-02-13",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "02\/12\/2026",
            "status": "Passed by for the day",
            "date_raw": "2026-02-12",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "02\/12\/2026",
            "status": "Passed by for the day  Block Vote (Voice Vote)",
            "date_raw": "2026-02-12",
            "vote_count": null,
            "lis_vote_id": "296922",
            "translation": null
        },
        {
            "date": "02\/12\/2026",
            "status": "Constitutional reading dispensed  Block Vote (on 1st reading) (40-Y 0-N 0-A)",
            "date_raw": "2026-02-12",
            "vote_count": null,
            "lis_vote_id": "296921",
            "translation": null
        },
        {
            "date": "02\/12\/2026",
            "status": "Rules suspended",
            "date_raw": "2026-02-12",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "02\/11\/2026",
            "status": "Reported from Finance and Appropriations with substitute (15-Y 0-N)",
            "date_raw": "2026-02-11",
            "vote_count": null,
            "lis_vote_id": "296207",
            "translation": "passed committee"
        },
        {
            "date": "02\/11\/2026",
            "status": "Reported from Finance and Appropriations with substitute",
            "date_raw": "2026-02-11",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": "passed committee"
        },
        {
            "date": "01\/30\/2026",
            "status": "Committee substitute printed 26106505D-S1",
            "date_raw": "2026-01-30",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "01\/29\/2026",
            "status": "Reported from Education and Health with substitute and rereferred to Finance and Appropriations (9-Y 0-N 6-A)",
            "date_raw": "2026-01-29",
            "vote_count": null,
            "lis_vote_id": "293017",
            "translation": "passed committee"
        },
        {
            "date": "01\/29\/2026",
            "status": "Reported from Education and Health with substitute and rereferred to Finance and Appropriations",
            "date_raw": "2026-01-29",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": "passed committee"
        },
        {
            "date": "01\/29\/2026",
            "status": "Senate committee offered",
            "date_raw": "2026-01-29",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "01\/28\/2026",
            "status": "Senate subcommittee offered",
            "date_raw": "2026-01-28",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "01\/27\/2026",
            "status": "Fiscal Impact Statement from Department of Planning and Budget (SB278)",
            "date_raw": "2026-01-27",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "01\/20\/2026",
            "status": "Assigned Education sub: Health",
            "date_raw": "2026-01-20",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": "in subcommittee"
        },
        {
            "date": "01\/13\/2026",
            "status": "Referred to Committee on Education and Health",
            "date_raw": "2026-01-13",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": "in committee"
        },
        {
            "date": "01\/13\/2026",
            "status": "Prefiled and ordered printed; Offered 01-14-2026 26102079D",
            "date_raw": "2026-01-13",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": "introduced"
        }
    ],
    "chief_patron_id": 523,
    "date_introduced": "2026-01-13",
    "patron_district": 32,
    "patron_shortname": "ksrinivasan",
    "committee_chamber": "senate",
    "status_detail_date": "04\/13\/2026",
    "committee_shortname": "finance",
    "patron_name_formatted": "Sen. Kannan Srinivasan (D-Loudoun)"
}